Market Cap (In USD)
12.86 Million
Revenue (In USD)
-
Net Income (In USD)
-19.51 Million
Avg. Volume
2348.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.49428-1.53
- PE
- -0.2218
- EPS
- -3.968
- Beta Value
- 2.134
- ISIN
- US15117N6022
- CUSIP
- -
- CIK
- -
- Shares
- 14620700.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Dr. Stacy R. Lindborg Ph.D.
- Employee Count
- -
- Website
- https://celsion.com
- Ipo Date
- 2018-01-29
- Details
- Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
More Stocks
-
0G1TWavestone SA
0G1T
-
CLSZF
-
300814
-
300718
-
300991
-
EXAIExpert.ai S.p.A.
EXAI
-
LIMFFLi-Metal Corp.
LIMFF
-
MMSDF